Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 13, 2010
Lead Product(s) : Urate Oxidase
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable